Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer
Xintong Li, Ze Zhang, Fangyan Gao, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 16, pp. 9334-9342
Closed Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 18
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Xiaowei Huang, Fengbo Wu, Jing Ye, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 6, pp. 2402-2427
Open Access | Times Cited: 16
Modified nucleic acid aptamers: development, characterization, and biological applications
Danyang Ji, Hengxin Feng, Shiau Wei Liew, et al.
Trends in biotechnology (2023) Vol. 41, Iss. 11, pp. 1360-1384
Closed Access | Times Cited: 33
Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems
Wan Su Yun, Soo Hyun Kim, Dong-Kwon Lim, et al.
Nanomaterials (2023) Vol. 13, Iss. 15, pp. 2225-2225
Open Access | Times Cited: 28
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Barmak Mostofian, Holli‐Joi Martin, Asghar M. Razavi, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 17, pp. 5408-5432
Open Access | Times Cited: 27
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy
Zhifeng Zou, Lei Yang, Hui-Jun Nie, et al.
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 8, pp. 1740-1751
Closed Access | Times Cited: 14
Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1
Zhen Wang, Dingpeng Zhang, Xing Qiu, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 11, pp. 7584-7593
Open Access | Times Cited: 12
Enzymatic Synthesis of TNA Protects DNA Nanostructures
Bohe Qin, Qi Wang, Yuang Wang, et al.
Angewandte Chemie International Edition (2024) Vol. 63, Iss. 13
Closed Access | Times Cited: 11
An engineered DNA aptamer-based PROTAC for precise therapy of p53-R175H hotspot mutant-driven cancer
Lingping Kong, Fanlu Meng, Ping Zhou, et al.
Science Bulletin (2024) Vol. 69, Iss. 13, pp. 2122-2135
Open Access | Times Cited: 10
Antitumor Effect of Anti‐c‐Myc Aptamer‐Based PROTAC for Degradation of the c‐Myc Protein
Yuchun Wang, Gang Yang, Xinyu Zhang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Closed Access | Times Cited: 9
Leveraging aptamers for targeted protein degradation
Zhihao Yang, Qiuxiang Pang, Jun Zhou, et al.
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 776-785
Closed Access | Times Cited: 21
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 21
Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells
Shaghayegh Saharkhiz, Negar Nasri, Nazanin Naderi, et al.
International Journal of Pharmaceutics X (2024) Vol. 7, pp. 100237-100237
Open Access | Times Cited: 6
Turning foes to friends: Advanced “in situ nanovaccine” with dual immunoregulation for enhanced immunotherapy of metastatic triple-negative breast cancer
Ze Wang, Tong Sha, Jinwei Li, et al.
Bioactive Materials (2024) Vol. 39, pp. 612-629
Open Access | Times Cited: 6
Engineering artificial non-coding RNAs for targeted protein degradation
Congcong Cao, Aolin Li, Chaojie Xu, et al.
Nature Chemical Biology (2024)
Closed Access | Times Cited: 6
MYC in liver cancer: mechanisms and targeted therapy opportunities
Furong Liu, Zhibin Liao, Zhanguo Zhang
Oncogene (2023) Vol. 42, Iss. 45, pp. 3303-3318
Closed Access | Times Cited: 14
Potential of the nanoplatform and PROTAC interface to achieve targeted protein degradation through the Ubiquitin–Proteasome system
Hanshu Xie, Chao Zhang
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116168-116168
Closed Access | Times Cited: 5
Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer
Long Lin, Xiangyu Fei, Liucui Chen, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 5
PROTAC: Novel degradable approach for different targets to treat breast cancer
Zhenjie Wang, Siyao Che, Zhiqiang Yu
European Journal of Pharmaceutical Sciences (2024) Vol. 198, pp. 106793-106793
Open Access | Times Cited: 5
Selection of biofilm-inhibiting ssDNA aptamers against antibiotic-resistant Edwardsiella tarda by inhibition-SELEX and interaction with their binding proteins
Yunting Fan, Jiang Zheng, Ying Tan, et al.
International Journal of Biological Macromolecules (2025), pp. 140041-140041
Closed Access
Myogenesis gone awry: the role of developmental pathways in rhabdomyosarcoma
Annika Gustafson, Adam D. Durbin, Kristin Artinger, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
PROTAC technology for prostate cancer treatment
Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
PROTACs coupled with oligonucleotides to tackle the undruggable
Guangshuai Zhang, Si Yan, Yan Liu, et al.
Bioanalysis (2025), pp. 1-16
Closed Access
Systematic evolution of functional oligonucleotides for targeted protein degradation
Huang Su, Yifan Chen, Xuyang Zhao, et al.
Chem (2025), pp. 102408-102408
Closed Access
MYC in cancer: from undruggable target to clinical trials
Jonathan R. Whitfield, Laura Soucek
Nature Reviews Drug Discovery (2025)
Closed Access
Page 1 - Next Page

Scroll to top